|Age:||-1 years or older|
|Keywords:||breast cancer, Hormone Receptor-Negative Breast Cancer, extension study|
The study team will make sure you qualify to take part in the study. Qualified participants will receive detailed information about the study. This may include a list of study-related tests and procedures.
Patients must be women concurrently enrolling to Alliance A011502.
Eligible patients may be either pre- or post-menopausal.
Patients must have hormone receptor-negative breast cancer.
Patients must have baseline breast density measurement as defined by one of the following: 1) ≥ 25% breast density, or 2) scattered areas of fibroglandular density, or 3) breast composition category b, c, or d, per BI-RADS 2013
Baseline digital mammogram with at least a mediolateral (MLO) and a craniocaudal (CC) view taken prior to all cancer treatment and within 8 weeks prior to registration must be available for submission.
Patients receiving endocrine therapy (e.g., tamoxifen, aromatase inhibitors) are not eligible.
Contralateral unaffected breast in place (with no prior cancer or radiation, no implants and no plan for breast surgery on contralateral breast over the course of the study). Patients with a prior biopsy on the unaffected breast are eligible.
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.